Inflammatory response in hematopoietic stem and progenitor cells triggered by activating SHP2 mutations evokes blood defects
- Hubrecht Institute-KNAW, Netherlands
- Hôpital Robert Debré, France
- Massachusetts General Hospital, United States
- University Medical Center Utrecht, Netherlands
Abstract
Gain-of-function mutations in the protein-tyrosine phosphatase SHP2 are the most frequently occurring mutations in sporadic juvenile myelomonocytic leukemia (JMML) and JMML-like myeloproliferative neoplasm (MPN) associated with Noonan syndrome (NS). Hematopoietic stem and progenitor cells (HSPCs) are the disease propagating cells of JMML. Here, we explored transcriptomes of HSPCs with Shp2 mutations derived from JMML patients and a novel NS zebrafish model. In addition to major NS traits, CRISPR/Cas9 knock-in Shp2D61G mutant zebrafish recapitulated a JMML-like MPN phenotype, including myeloid lineage hyperproliferation, ex vivo growth of myeloid colonies and in vivo transplantability of HSPCs. Single cell mRNA sequencing of HSPCs from Shp2D61G zebrafish embryos and bulk sequencing of HSPCs from JMML patients revealed an overlapping inflammatory gene expression pattern. Strikingly, an anti-inflammatory agent rescued JMML-like MPN in Shp2D61G zebrafish embryos. Our results indicate that a common inflammatory response was triggered in the HSPCs from sporadic JMML patients and syndromic NS zebrafish, which potentiated MPN and may represent a future target for JMML therapies.
Data availability
Sequencing data has been deposited to GEO under accession codes GSE167787 and GSE183252Figure 1-Source Data 1, Figure 3-Source Data 1 and Figure 5-Source Data 1-3 contain the source data for the respective figures
-
Inflammation potentiates JMML-like blood defects in Shp2 mutant Noonan syndromeNCBI Gene Expression Omnibus, GSE167787.
-
Inflammatory response in HSPC of PTPN11-mutated JMMLNCBI Gene Expression Omnibus, GSE183252.
Article and author information
Author details
Funding
European Commission (ERARE NSEURONET)
- Jeroen den Hertog
European Commission (EJPRD NSEURONET)
- Helene Cave
European Commission (EJPRD NSEURONET)
- Jeroen den Hertog
KWF Kankerbestrijding (12829)
- Jeroen den Hertog
NIH Office of the Director (R01CA211734)
- David M Langenau
NIH Office of the Director (R24OD016761)
- David M Langenau
European Commission (ERARE NSEURONET)
- Helene Cave
The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.
Reviewing Editor
- Richard M White, Memorial Sloan Kettering Cancer Center, United States
Ethics
Animal experimentation: All procedures involving experimental animals were approved by the animal experiments committee of the Royal Netherlands Academy of Arts and Sciences (KNAW), Dierexperimenten commissie protocol HI18-0702, and performed under the local guidelines in compliance with national and European law.
Human subjects: All children's samples were obtained after parents had given their written informed consent. Experiments were approved by the institutional review board of the French Institute of Health and Medical Research (INSERM) (IORG0003254) in accordance with the Helsinki declaration. Healthy children bone marrows were obtained from intrafamilial BM transplantation donors and used with the approval of the Institutional Review Board of "Hôpitaux Universitaires Paris Nord Val-de-Seine," Paris 7 University, AP-HP), (IRB: 00006477), in accordance with the Helsinki declaration.
Version history
- Preprint posted: September 10, 2020 (view preprint)
- Received: August 13, 2021
- Accepted: April 20, 2022
- Accepted Manuscript published: May 10, 2022 (version 1)
- Version of Record published: May 19, 2022 (version 2)
Copyright
© 2022, Solman et al.
This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.
Metrics
-
- 1,457
- views
-
- 230
- downloads
-
- 11
- citations
Views, downloads and citations are aggregated across all versions of this paper published by eLife.
Download links
A two-part list of links to download the article, or parts of the article, in various formats.
Downloads (link to download the article as PDF)
Open citations (links to open the citations from this article in various online reference manager services)
Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)
Inflammatory response in hematopoietic stem and progenitor cells triggered by activating SHP2 mutations evokes blood defects
eLife 11:e73040.
https://doi.org/10.7554/eLife.73040
Further reading
-
- Cancer Biology
- Genetics and Genomics
Relapse of acute myeloid leukemia (AML) is highly aggressive and often treatment refractory. We analyzed previously published AML relapse cohorts and found that 40% of relapses occur without changes in driver mutations, suggesting that non-genetic mechanisms drive relapse in a large proportion of cases. We therefore characterized epigenetic patterns of AML relapse using 26 matched diagnosis-relapse samples with ATAC-seq. This analysis identified a relapse-specific chromatin accessibility signature for mutationally stable AML, suggesting that AML undergoes epigenetic evolution at relapse independent of mutational changes. Analysis of leukemia stem cell (LSC) chromatin changes at relapse indicated that this leukemic compartment underwent significantly less epigenetic evolution than non-LSCs, while epigenetic changes in non-LSCs reflected overall evolution of the bulk leukemia. Finally, we used single-cell ATAC-seq paired with mitochondrial sequencing (mtscATAC) to map clones from diagnosis into relapse along with their epigenetic features. We found that distinct mitochondrially-defined clones exhibit more similar chromatin accessibility at relapse relative to diagnosis, demonstrating convergent epigenetic evolution in relapsed AML. These results demonstrate that epigenetic evolution is a feature of relapsed AML and that convergent epigenetic evolution can occur following treatment with induction chemotherapy.
-
- Cancer Biology
- Cell Biology
Rapid recovery of proteasome activity may contribute to intrinsic and acquired resistance to FDA-approved proteasome inhibitors. Previous studies have demonstrated that the expression of proteasome genes in cells treated with sub-lethal concentrations of proteasome inhibitors is upregulated by the transcription factor Nrf1 (NFE2L1), which is activated by a DDI2 protease. Here, we demonstrate that the recovery of proteasome activity is DDI2-independent and occurs before transcription of proteasomal genes is upregulated but requires protein translation. Thus, mammalian cells possess an additional DDI2 and transcription-independent pathway for the rapid recovery of proteasome activity after proteasome inhibition.
